SREBF1 and chronic kidney disease: It was demonstrated that cisplatin‐induced METTL3‐mediated m6A modification increased the mRNA stability of SREBP1c, thereby upregulating its expression, while depletion of SREBP1c markedly ameliorated cisplatin‐induced AKI and its progression to CKD.